Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy

Journal of Drug Targeting

Volumn 20, Issue 3, 2012, Pages 264-271

  Li, Chong ^a,b   Shen, Jie ^a   Wei, Xiaoli ^a   Xie, Cao ^a   Lu, Weiyue ^a  

^a FUDAN UNIVERSITY   (China)

^b SOUTHWEST UNIVERSITY   (China)

Author keywords

Cyclic RGD decorated liposomes; D peptide; Glioblastoma; Lipophilic peptide; P53

Indexed keywords

DOXORUBICIN; LIPOSOME; PALMITIC ACID; PENTAPEPTIDE; PENTAPEPTIDE PDP; PENTAPEPTIDE RGDYK; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; MALE; MOLECULAR THERAPY; MOUSE; NONHUMAN; PALMITOYLATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SURVIVAL RATE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ACYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG COMPOUNDING; GLIOBLASTOMA; HUMANS; LIPOPEPTIDES; LIPOSOMES; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PALMITIC ACID; PEPTIDES, CYCLIC; PROTO-ONCOGENE PROTEINS C-MDM2; RANDOM ALLOCATION; STEREOISOMERISM; SURFACE PROPERTIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863230569     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.645162     Document Type: Article

References (40)

1. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. (2007). Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc, 129, 2456-2457.
2. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS. (2004a). Pegylated Arg-Gly- Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med, 45, 1776-1783.
3. Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, Bading JR, Moats R, Laug WE, Conti PS. (2004b). 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol, 31, 179-189.
4. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
5. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. (2007). Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res, 13, 3380-3387.
6. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. (2009). Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia, 11, 145-156.
7. Gupta B, Torchilin VP. (2007). Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother, 56, 1215-1223.
8. Honda R, Tanaka H, Yasuda H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420, 25-27.
9. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X. (2006). In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol, 8, 315-323.
10. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. (2009). Lactoferrinconjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release, 134, 55-61.
11. Kirsch DG, Kastan MB. (1998). Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol, 16, 3158-3168.
12. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. (2005). MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood, 106, 3150-3159.
13. Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA. (2002). Targeting glioblastoma multiforme with an IL-13/ diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng, 15, 419-427.
14. Li C, Liu M, Monbo J, Zou G, Li C, Yuan W, Zella D, Lu WY, Lu W. (2008). Turning a scorpion toxin into an antitumor miniprotein. J Am Chem Soc, 130, 13546-13548.
15. Liang MT, Davies NM, Toth I. (2005). Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int J Pharm, 301, 247-254.
16. Liu Y, Huang R, Han L, Ke W, Shao K, Ye L, Lou J, Jiang C. (2009). Braintargeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials, 30, 4195-4202.
17. Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, Gu B, Wei G, Yuan W, Zhan C, Lu WY, Lu W. (2010a). D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci USA, 107, 14321-14326.
18. Liu Y, Pan Y, Xu Y. (2010b). Binding investigation of integrin alphavbeta3 with its inhibitors by SPR technology and molecular docking simulation. J Biomol Screen, 15, 131-137.
19. Liu M, Pazgier M, Li C, Yuan W, Li C, Lu W. (2010c). A left-handed solution to peptide inhibition of the p53-MDM2 interaction. Angew Chem Int Ed Engl, 49, 3649-3652.
20. Madhankumar AB, Slagle-Webb B, Wang X, Yang QX, Antonetti DA, Miller PA, Sheehan JM, Connor JR. (2009). Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther, 8, 648-654.
21. Magrini R, Bakker A, Gaviraghi G, Terstappen GC. (2006). Targeting the p53 tumor suppressor gene function in glioblatomas using small chemical molecules. Drug Dev Res, 67, 790-800.
22. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der Auwera I, van Leuven F, Sugawara M, Weingertner MC, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C. (2007). Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA, 104, 9810-9815.
23. Naganuma H, Satoh E, Asahara T, Amagasaki K, Watanabe A, Satoh H, Kuroda K, Zhang L, Nukui H. (2004). Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. J Neurooncol, 70, 309-317.
24. Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ. (2002). A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci USA, 99, 2332-2337.
25. Pan H, Han L, Chen W, Yao M, Lu W. (2008). Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release, 125, 228-235.
26. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-1812.
27. Prasad G, Wang H, Agrawal S, Zhang R. (2002). Antisense anti- MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res, 22, 107-116.
28. Schumacher TN, Mayr LM, Minor DL Jr, Milhollen MA, Burgess MW, Kim PS. (1996). Identification of D-peptide ligands through mirrorimage hage display. Science, 271, 1854-1857.
29. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A, Zauli G. (2007). Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res, 100, 61-69.
30. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA, 105, 3933-3938.
31. Slimani H, Guenin E, Briane D, Coudert R, Charnaux N, Starzec A, Vassy R, Lecouvey M, Perret YG, Cao A. (2006). Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1. J Drug Target, 14, 694-706.
32. Toledo F, Wahl GM. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer, 6, 909-923.
33. Tosi PF, Radu D, Nicolau C. (1995). Immune response against the murine mdri protein induced by vaccination with synthetic lipopeptides in liposomes. Biochem Biophys Res Commun, 212, 494-500.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-848.
35. Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, Jin C, Hsu AR, Connolly AJ, Tse V, Wang F, Chen X. (2008). Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res, 14, 7330-7339.
36. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature, 408, 307-310.
37. Wang XL, Xu R, Wu X, Gillespie D, Jensen R, Lu ZR. (2009). Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm, 6, 738-746.
38. Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q. (2010). Dualtargeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release, 141, 183-192.
39. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. (2010). Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release, 143, 136-142.
40. Zhang L, Zhang J, Hu C, Cao J, Zhou X, Hu Y, He Q, Yang B. (2009). Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction. Anticancer Drugs, 20, 416-424.